Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 11 - 12 tags : Therapy save search
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Published: 2021-11-12 (Crawled : 16:20) - investors.senseibio.com
SNSE | $1.01 8.5% 7.83% 85K
|
|
| O: -1.15%
H: 0.0%
C: 0.0%
preclinical immunotherapy therapy cancer antibody iot pre-clinical
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B
Published: 2021-11-12 (Crawled : 23:00) - biospace.com/
SRRK 4 | $14.79 5.64% 5.34% 740K
|
Health Technology
|
| O: -0.35%
H: 3.45%
C: 2.09%
treatment solid tumors phase 1 therapy trial
Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021
Published: 2021-11-12 (Crawled : 23:00) - biospace.com/
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: -35.41%
H: 1.67%
C: -15.76%
immunotherapy ongoing phase 1 positive therapy
Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results
Published: 2021-11-12 (Crawled : 23:00) - biospace.com/
ROIV | $10.935 3.16% 3.06% 5M
|
Manufacturing
|
| O: -0.38%
H: 9.11%
C: 7.83%
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: -4.48%
H: 4.17%
C: 3.65%
financial results gene therapies results therapy gene therapy
Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Published: 2021-11-12 (Crawled : 23:00) - biospace.com/
REPL | $6.41 -0.16% -0.16% 1.2M
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
immunotherapy therapy cancer
Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting
Published: 2021-11-12 (Crawled : 23:00) - biospace.com/
XLO | $1.06 -3.64% -3.77% 450K
|
Professional, Scientific, and T...
|
| O: -3.14%
H: 0.07%
C: -3.67%
preclinical immunotherapy therapy cancer pre-clinical
Second Genome Presents Preclinical Data at SITC 2021 Demonstrating that a CXCR3-Positive Allosteric Modulator, SG-3-00802, Targets a Key Mechanism Required for Efficacious Immunotherapy
Published: 2021-11-12 (Crawled : 23:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
preclinical immunotherapy positive therapy pre-clinical
Aimmune Therapeutics Presents New PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital Meeting
Published: 2021-11-12 (Crawled : 22:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
|
| O: 8.62%
H: 0.0%
C: -1.59%
immunotherapy therapy
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2021-11-12 (Crawled : 22:00) - biospace.com/
IOVA M | $11.86 4.77% 4.55% 3.9M
|
Health Technology
|
| O: -2.55%
H: 0.0%
C: 0.0%
immunotherapy lung cancer therapy cancer iot
SQZ Biotechnologies Presents New AAC, eAPC Platform Research and First Enhanced Tumor Infiltrating Lymphocyte Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting
Published: 2021-11-12 (Crawled : 22:00) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: -5.84%
H: 5.11%
C: 2.41%
preclinical immunotherapy therapy cancer biotech research iot platform pre-clinical
Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
GTHX | $4.19 2.2% 2.15% 350K
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: 0.0%
phase 2 therapy cancer breast cancer trial trilaciclib t-cell
Actinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
ATNM | $6.96 -2.93% -1.14% 190K
|
Health Technology
|
| O: 2.08%
H: 0.0%
C: 0.0%
immunotherapy solid tumors therapy cancer iot conference her2+ her2- her2
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: 0.0%
immunotherapy therapy cancer conference
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
CLLS | News | $2.535 -3.98% -4.14% 47K
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
immunotherapy solid tumors therapy car-t cancer ucartmeso preclinical t-cell pre-clinical
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
NRIX 6 d | $14.125 4.01% 3.86% 690K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
treatment solid tumors potential therapy drug clearance t-cell
Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
BDSX | $1.275 -1.16% -1.18% 37K
|
Health Services
|
| O: -1.5%
H: 0.0%
C: 0.0%
immunotherapy test therapy cancer diagnostic
Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021
Published: 2021-11-12 (Crawled : 12:15) - prnewswire.com
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
heart therapy
Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Published: 2021-11-12 (Crawled : 12:15) - celyad.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
immunotherapy therapy cancer trial car-t preclinical pre-clinical designation
Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2021-11-12 (Crawled : 12:00) - prnewswire.com
NKTR | News | $1.415 4.04% 3.89% 1.1M
|
Health Technology
|
| O: 2.01%
H: 0.0%
C: 0.0%
presentation immunotherapy therapy cancer
Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021
Published: 2021-11-12 (Crawled : 12:00) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: -10.51%
H: 0.0%
C: 0.0%
phase 1 therapy results antibody
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.